GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Universal Vision Biotechnology Co Ltd (ROCO:3218) » Definitions » Debt-to-Equity

Universal Vision Biotechnology Co (ROCO:3218) Debt-to-Equity : 0.25 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Universal Vision Biotechnology Co Debt-to-Equity?

Universal Vision Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$165 Mil. Universal Vision Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$613 Mil. Universal Vision Biotechnology Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$3,178 Mil. Universal Vision Biotechnology Co's debt to equity for the quarter that ended in Dec. 2023 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Universal Vision Biotechnology Co's Debt-to-Equity or its related term are showing as below:

ROCO:3218' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07   Med: 0.28   Max: 0.37
Current: 0.25

During the past 13 years, the highest Debt-to-Equity Ratio of Universal Vision Biotechnology Co was 0.37. The lowest was 0.07. And the median was 0.28.

ROCO:3218's Debt-to-Equity is ranked worse than
53.15% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 0.215 vs ROCO:3218: 0.25

Universal Vision Biotechnology Co Debt-to-Equity Historical Data

The historical data trend for Universal Vision Biotechnology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Vision Biotechnology Co Debt-to-Equity Chart

Universal Vision Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.32 0.35 0.29 0.25

Universal Vision Biotechnology Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.34 0.30 0.27 0.25

Competitive Comparison of Universal Vision Biotechnology Co's Debt-to-Equity

For the Medical Devices subindustry, Universal Vision Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Vision Biotechnology Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Universal Vision Biotechnology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Universal Vision Biotechnology Co's Debt-to-Equity falls into.



Universal Vision Biotechnology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Universal Vision Biotechnology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Universal Vision Biotechnology Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Vision Biotechnology Co  (ROCO:3218) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Universal Vision Biotechnology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Universal Vision Biotechnology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Vision Biotechnology Co (ROCO:3218) Business Description

Traded in Other Exchanges
N/A
Address
No. 3-1, Yuanyuan Street, 4th Floor, Nangang District, Taipei, TWN, 115
Universal Vision Biotechnology Co Ltd provides eye treatment and related medical services in Taiwan. It also provides optical devices, glasses, lens and other vision aid products, optometric services, sales and leasing of medical devices, providing of hospital management and technical consultancy services.

Universal Vision Biotechnology Co (ROCO:3218) Headlines

No Headlines